These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5149 related articles for article (PubMed ID: 3546184)

  • 1. Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent.
    Chun HG; Davies B; Hoth D; Suffness M; Plowman J; Flora K; Grieshaber C; Leyland-Jones B
    Invest New Drugs; 1986; 4(3):279-84. PubMed ID: 3546184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral and antitumor compounds from tunicates.
    Rinehart KL; Gloer JB; Wilson GR; Hughes RG; Li LH; Renis HE; McGovren JP
    Fed Proc; 1983 Jan; 42(1):87-90. PubMed ID: 6681537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antineoplastic activity of didemnin congeners: nordidemnin and modified chain analogues.
    Jouin P; Poncet J; Dufour MN; Aumelas A; Pantaloni A; Cros S; François G
    J Med Chem; 1991 Feb; 34(2):486-91. PubMed ID: 1995869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and cellular effects of didemnins A and B.
    Crampton SL; Adams EG; Kuentzel SL; Li LH; Badiner G; Bhuyan BK
    Cancer Res; 1984 May; 44(5):1796-801. PubMed ID: 6713383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Didemnins: antiviral and antitumor depsipeptides from a caribbean tunicate.
    Rinehart KL; Gloer JB; Hughes RG; Renis HE; McGovren JP; Swynenberg EB; Stringfellow DA; Kuentzel SL; Li LH
    Science; 1981 May; 212(4497):933-5. PubMed ID: 7233187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I clinical trial of didemnin B.
    Stewart JA; Low JB; Roberts JD; Blow A
    Cancer; 1991 Dec; 68(12):2550-4. PubMed ID: 1933801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of didemnin B, a depsipeptide from the sea.
    Li LH; Timmins LG; Wallace TL; Krueger WC; Prairie MD; Im WB
    Cancer Lett; 1984 Jul; 23(3):279-88. PubMed ID: 6744252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural products as probes of cell biology: 20 years of didemnin research.
    Vera MD; Joullié MM
    Med Res Rev; 2002 Mar; 22(2):102-45. PubMed ID: 11857636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-tumor marine natural products].
    Kitagawa I; Kobayashi M
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):322-9. PubMed ID: 2310201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure--activity relationships of the didemnins.
    Sakai R; Rinehart KL; Kishore V; Kundu B; Faircloth G; Gloer JB; Carney JR; Namikoshi M; Sun F; Hughes RG; García Grávalos D; de Quesada TG; Wilson GR; Heid RM
    J Med Chem; 1996 Jul; 39(14):2819-34. PubMed ID: 8709112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of didemnin B in the human tumor stem cell assay.
    Jiang TL; Liu RH; Salmon SE
    Cancer Chemother Pharmacol; 1983; 11(1):1-4. PubMed ID: 6883622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Didemnins and tunichlorin: novel natural products from the marine tunicate Trididemnum solidum.
    Rinehart KL; Kishore V; Bible KC; Sakai R; Sullins DW; Li KM
    J Nat Prod; 1988; 51(1):1-21. PubMed ID: 3373220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an Eastern Cooperative Oncology Group study (PB687).
    Hochster H; Oratz R; Ettinger DS; Borden E
    Invest New Drugs; 1998-1999; 16(3):259-63. PubMed ID: 10360606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
    Fujimoto K; Oka T; Morimoto M
    Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Verucopeptin, a new antitumor antibiotic active against B16 melanoma. I. Taxonomy, production, isolation, physico-chemical properties and biological activity.
    Nishiyama Y; Sugawara K; Tomita K; Yamamoto H; Kamei H; Oki T
    J Antibiot (Tokyo); 1993 Jun; 46(6):921-7. PubMed ID: 8344873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of didemnin B in advanced colorectal cancer.
    Jones DV; Ajani JA; Blackburn R; Daugherty K; Levin B; Patt YZ; Abbruzzese JL
    Invest New Drugs; 1992 Aug; 10(3):211-3. PubMed ID: 1428730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide.
    Dorr FA; Kuhn JG; Phillips J; von Hoff DD
    Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1699-706. PubMed ID: 3208814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A specific binding site in Nb2 node lymphoma cells mediates the effects of didemnin B, an immunosuppressive cyclic peptide.
    Shen GK; Zukoski CF; Montgomery DW
    Int J Immunopharmacol; 1992 Jan; 14(1):63-73. PubMed ID: 1582735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays.
    Geldof AA; Mastbergen SC; Henrar RE; Faircloth GT
    Cancer Chemother Pharmacol; 1999; 44(4):312-8. PubMed ID: 10447579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of Didemnin B in patients with advanced renal cell carcinoma.
    Motzer R; Scher H; Bajorin D; Sternberg C; Bosl GJ
    Invest New Drugs; 1990 Nov; 8(4):391-2. PubMed ID: 2084073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 258.